Thus, brexucabtagene autoleucel was specifically designed for the treatment of leukemic CD19-positive malignant diseases, e.g., mantle cell lymphoma (MCL) and B-cell leukemias [88]. Here, CD19 is linked to mantle cell lymphoma.